Literature DB >> 19575020

Hepatitis: HCV variability, the immune system and resistance to antiviral drugs.

Jean-Michel Pawlotsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19575020     DOI： 10.1038/nrgastro.2009.102

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  11 in total

1.  HIV drug resistance.

Authors:  François Clavel; Allan J Hance
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

Review 2.  Hepatitis C virus population dynamics during infection.

Authors:  J M Pawlotsky
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

3.  General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues.

Authors:  Hélène Dutartre; Cécile Bussetta; Joëlle Boretto; Bruno Canard
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

4.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors:  Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

5.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.

Authors:  Giovanni Migliaccio; Joanne E Tomassini; Steven S Carroll; Licia Tomei; Sergio Altamura; Balkrishen Bhat; Linda Bartholomew; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; Riccardo Cortese; Raffaele De Francesco; Anne B Eldrup; Krista L Getty; Xiaoli S Hou; Robert L LaFemina; Steven W Ludmerer; Malcolm MacCoss; Daniel R McMasters; Mark W Stahlhut; David B Olsen; Daria J Hazuda; Osvaldo A Flores
Journal:  J Biol Chem       Date:  2003-09-08       Impact factor: 5.157

7.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Authors:  Doug J Bartels; Yi Zhou; Eileen Z Zhang; Michelle Marcial; Randal A Byrn; Thomas Pfeiffer; Ann M Tigges; Bambang S Adiwijaya; Chao Lin; Ann D Kwong; Tara L Kieffer
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

8.  GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.

Authors:  Matthew F McCown; Sonal Rajyaguru; Simran Kular; Nick Cammack; Isabel Nájera
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

Authors:  Silvana Gaudieri; Andri Rauch; Katja Pfafferott; Eleanor Barnes; Wendy Cheng; Geoff McCaughan; Nick Shackel; Gary P Jeffrey; Lindsay Mollison; Ross Baker; Hansjakob Furrer; Huldrych F Günthard; Elizabeth Freitas; Isla Humphreys; Paul Klenerman; Simon Mallal; Ian James; Stuart Roberts; David Nolan; Michaela Lucas
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Authors:  Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M Berlin; Sarah K Young; Bongshin Lee; David Heckerman; Jonathan Carlson; Laura L Reyor; Marianna Kleyman; Cory M McMahon; Christopher Birch; Julian Schulze Zur Wiesch; Timothy Ledlie; Michael Koehrsen; Chinnappa Kodira; Andrew D Roberts; Georg M Lauer; Hugo R Rosen; Florian Bihl; Andreas Cerny; Ulrich Spengler; Zhimin Liu; Arthur Y Kim; Yanming Xing; Arne Schneidewind; Margaret A Madey; Jaquelyn F Fleckenstein; Vicki M Park; James E Galagan; Chad Nusbaum; Bruce D Walker; Gerond V Lake-Bakaar; Eric S Daar; Ira M Jacobson; Edward D Gomperts; Brian R Edlin; Sharyne M Donfield; Raymond T Chung; Andrew H Talal; Tony Marion; Bruce W Birren; Matthew R Henn; Todd M Allen
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425
View more
  8 in total

1.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

2.  Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.

Authors:  Atefeh Saeedi; Amir Ghaemi; Alijan Tabarraei; Abdolvahab Moradi; Ali Gorji; Shahryar Semnani; Hoorieh Soleimanjahi; Ahmad Hosseinzadeh Adli; Seyed Yones Hosseini; Mohammad Ali Vakili
Journal:  Virus Genes       Date:  2014-04-22       Impact factor: 2.332

3.  Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

Authors:  Malihe Naderi; Atefeh Saeedi; Abdolvahab Moradi; Mishar Kleshadi; Mohammad Reza Zolfaghari; Ali Gorji; Amir Ghaemi
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

Review 4.  Virologic Tools for HCV Drug Resistance Testing.

Authors:  Slim Fourati; Jean-Michel Pawlotsky
Journal:  Viruses       Date:  2015-12-04       Impact factor: 5.048

5.  New real-time-PCR method to identify single point mutations in hepatitis C virus.

Authors:  Qian Chen; Irene Belmonte; Maria Buti; Leonardo Nieto; Damir Garcia-Cehic; Josep Gregori; Celia Perales; Laura Ordeig; Meritxell Llorens; Maria Eugenia Soria; Rafael Esteban; Juan Ignacio Esteban; Francisco Rodriguez-Frias; Josep Quer
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

Review 6.  Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature.

Authors:  Mohit Bhatia; Ekta Gupta
Journal:  J Family Med Prim Care       Date:  2020-02-28

7.  Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.

Authors:  John M Murray; Rémy Moenne-Loccoz; Aurélie Velay; François Habersetzer; Michel Doffoël; Jean-Pierre Gut; Isabel Fofana; Mirjam B Zeisel; Françoise Stoll-Keller; Thomas F Baumert; Evelyne Schvoerer
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

8.  Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine.

Authors:  Mohammad-Hassan Pouriayevali; Taravat Bamdad; Mohammad-Reza Aghasadeghi; Seyed Mehdi Sadat; Farzaneh Sabahi
Journal:  Jundishapur J Microbiol       Date:  2016-03-19       Impact factor: 0.747
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.